Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
In the latest session, Bio-Techne Corp (NASDAQ: TECH) closed at $65.29 down -0.99% from its previous closing price of $65.94. In other words, the price has decreased by -$0.99 from its previous closing price. On the day, 1.51 million shares were traded.
Ratios:
For a deeper understanding of Bio-Techne Corp’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 58.13 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 40.59. For the most recent quarter (mrq), Quick Ratio is recorded 2.77 and its Current Ratio is at 3.94. In the meantime, Its Debt-to-Equity ratio is 0.19 whereas as Long-Term Debt/Eq ratio is at 0.18.
On February 08, 2024, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $80.
Stifel Downgraded its Buy to Hold on February 02, 2024, while the target price for the stock was maintained at $65.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Feb 14 ’25 when Herr Amy E. sold 1,860 shares for $65.96 per share. The transaction valued at 122,691 led to the insider holds 1,976 shares of the business.
JOSHUA MOLHO bought 1,860 shares of TECH for $122,691 on Feb 14 ’25. On Jan 27 ’25, another insider, Kelderman Kim, who serves as the Chief Executive Officer of the company, sold 13,392 shares for $77.29 each. As a result, the insider received 1,035,013 and left with 39,004 shares of the company.
Valuation Measures:
As of this moment, Bio-Techne’s Price-to-Earnings (P/E) ratio for their current fiscal year is 66.36, and their Forward P/E ratio for the next fiscal year is 29.90. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 5.18. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.63 while its Price-to-Book (P/B) ratio in mrq is 4.96.
Stock Price History:
Over the past 52 weeks, TECH has reached a high of $85.57, while it has fallen to a 52-week low of $61.16. The 50-Day Moving Average of the stock is -11.40%, while the 200-Day Moving Average is calculated to be -12.79%.
Shares Statistics:
A total of 157.92M shares are outstanding, with a floating share count of 156.26M. Insiders hold about 1.15% of the company’s shares, while institutions hold 100.13% stake in the company.
Earnings Estimates
The dynamic stock of Bio-Techne Corp (TECH) is currently attracting attention from 11.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is $0.55, with high estimates of $0.56 and low estimates of $0.52.
Analysts are recommending an EPS of between $1.92 and $1.86 for the fiscal current year, implying an average EPS of $1.9. EPS for the following year is $2.2, with 13.0 analysts recommending between $2.4 and $2.0.
Revenue Estimates
A total of 12 analysts believe the company’s revenue will be $317.76M this quarter.It ranges from a high estimate of $320.3M to a low estimate of $314.56M. As of the current estimate, Bio-Techne Corp’s year-ago sales were $303.43MFor the next quarter, 12 analysts are estimating revenue of $326.81M. There is a high estimate of $332.4M for the next quarter, whereas the lowest estimate is $320.92M.
A total of 14 analysts have provided revenue estimates for TECH’s current fiscal year. The highest revenue estimate was $1.24B, while the lowest revenue estimate was $1.22B, resulting in an average revenue estimate of $1.23B. In the same quarter a year ago, actual revenue was $1.16BBased on 13 analysts’ estimates, the company’s revenue will be $1.34B in the next fiscal year. The high estimate is $1.37B and the low estimate is $1.31B.
